Printer Friendly

Anaconda Biomed secures EUR15m in Series A financing.

M2 EQUITYBITES-May 23, 2017-Anaconda Biomed secures EUR15m in Series A financing

(C)2017 M2 COMMUNICATIONS http://www.m2.com

A Series A financing round for Anaconda Biomed has closed at EUR15m, the private Spanish company disclosed on Tuesday.

The round was led by new investors Ysios Capital (Barcelona, Spain), Omega Funds (Boston, USA), Banco Sabadell (Spain), and current investor Innogest Capital (Milan, Italy).

Following the financing, Anaconda Biomed's board of directors will be joined by Josep L. Sanfeliu, general partner at Ysios Capital, and Claudio Nessi, MD at Omega Funds. Innogest Capital will continue to be represented by Giovanni Leo.

Anaconda Biomed is focused on developing the next generation of neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS).

Discussing the financing round, Claudio Rumazza, partner at Innogest Capital, said: "With its innovative design addressing a clear clinical need and a capable management team, Anaconda Biomed is well positioned to be a winner in the high growth stroke treatment market and a success story for European medtech industry."

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Geographic Code:4EUSP
Date:May 23, 2017
Words:180
Previous Article:Zebinix granted EU marketing authorisation as once-daily monotherapy.
Next Article:Biosimilars are significantly increasing patient access to drugs across Europe.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters